What is immune effector cell associated hematotoxicity (ICHAT)? Which myeloma therapies are associated with ICHAT? How is ICHAT managed?

What is immune effector cell associated hematotoxicity (ICHAT)? Which myeloma therapies are associated with ICHAT? How is ICHAT managed?
New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025
What should I know abut visitors during the ASCT process?
Unmet Medical Needs of Patients Who are Lenalidomide Refractory | Claudio Cerchione, MD | #EHA2025
Does Race Have an Impact on CLL Care? What the Latest Data? | Adam Kittai, MD #EHA2025
Could Clonotypic B Cells Be the Key to Myeloma & AL Amyloidosis Origins? | Bruno Paiva, PhD | EHA25
When can I expect to feel better after transplant?
All-Oral Myeloma Combo: Mezigdomide + Tazemetostat or Trametinib | Paul Richardson, MD | EHA 2025
Slowing CAR-T Cell Expansion with Steroids 2 Prevent Delayed Neurotoxicity | Yi Lin, MD | #EHA2025
How long will I be immunocompromised? How can I prevent infection after transplant?
How long is the average stay for an ASCT? How will the doctor know when I am able to return home or no longer come for daily clinic visits?
Belantamab Mafodotin Updates & How to Manage Eye Side Effects | Evangelos Terpos, MD, PhD | #EHA2025